Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
The Role of Eosinophils in Allergic Inflammation Indicated by the Effect of Anti-IL-5 Therapy to Asthma
Journal ArticleDOI
Bloqueo de inmunoglobulina E en el asma grave
TL;DR: Preclinical and clinical evidence supports the existence of close counter-regulation of high-affinity immunoglobulin E receptor and interferon pathways, and a possible mechanism of prevention of virus-induces exacerbations in severe asthma.
Journal ArticleDOI
ÉditorialAnti-IgE : au-delà des recommandationsAnti-IgE: Beyond recommendations
F. Lavaud,G. Dutau +1 more
Omalizumab no tratamento da asma brônquica alérgica: Experiência num Serviço de Imunoalergologia
José Geraldo Dias,Pedro Morais Silva,Ana Magnólia Mendes,Célia Costa,Elisa Pedro,Manuel Pereira Barbosa +5 more
TL;DR: Omalizumab seems to be effective as add -on therapy, in patients with uncontrolled severe allergic asthma despite high dose of IC and LABA, and allowed suspension of OC in a short period of time.
Journal ArticleDOI
Phenotyping asthma: More complex than just age.
TL;DR: In this article, the authors proposed a method to solve the problem of the problem: this article ] of unstructured data mining, which can be found here: http://github.com/
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.